Saltar al contenido
Merck

Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury.

PloS one (2014-05-14)
Ke Wang, Li Wen, Wenhui Peng, Hailing Li, Jianhui Zhuang, Yuyan Lu, Baoxin Liu, Xiankai Li, Weiming Li, Yawei Xu
RESUMEN

Diabetes exacerbates abnormal vascular smooth muscle cell (VSMC) accumulation in response to arterial wall injury. Vinpocetine has been shown to improve vascular remolding; however, little is known about the direct effects of vinpocetine on vascular complications mediated by diabetes. The objective of this study was to determine the effects of vinpocetine on hyperglycemia-facilitated neointimal hyperplasia and explore its possible mechanism. Nondiabetic and diabetic rats were subjected to balloon injury of the carotid artery followed by 3-week treatment with either vinpocetine (10 mg/kg/day) or saline. Morphological analysis and proliferating cell nuclear antigen (PCNA) immunostaining were performed on day 21. Rat VSMCs proliferation was determined with 5-ethynyl-20-deoxyuridine cell proliferation assays. Chemokinesis was monitored with scratch assays, and production of reactive oxygen species (ROS) was assessed using a 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) flow cytometric assay. Apoptosis was detected by annexin V-FITC/PI flow cytometric assay. Cell signaling was assessed by immunblotting. Vinpocetine prevented intimal hyperplasia in carotid arteries in both normal (I/M ratio: 93.83 ± 26.45% versus 143.2 ± 38.18%, P<0.05) and diabetic animals (I/M ratio: 120.5 ± 42.55% versus 233.46 ± 33.98%, P<0.05) when compared to saline. The in vitro study demonstrated that vinpocetine significantly inhibited VSMCs proliferation and chemokinesis as well as ROS generation and apoptotic resistance, which was induced by high glucose (HG) treatment. Vinpocetine significantly abolished HG-induced phosphorylation of Akt and JNK1/2 without affecting their total levels. For downstream targets, HG-induced phosphorylation of IκBα was significantly inhibited by vinpocetine. Vinpocetine also attenuated HG-enhanced expression of PCNA, cyclin D1 and Bcl-2. Vinpocetine attenuated neointimal formation in diabetic rats and inhibited HG-induced VSMCs proliferation, chemokinesis and apoptotic resistance by preventing ROS activation and affecting MAPK, PI3K/Akt, and NF-κB signaling.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
D-(+)-Glucosa, ≥99.5% (GC)
Sigma-Aldrich
Estroptozocina, ≥75% α-anomer basis, ≥98% (HPLC), powder
Sigma-Aldrich
D-(+)-Glucosa, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
Colesterol, Sigma Grade, ≥99%
Sigma-Aldrich
Dextrosa, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
D-(+)-Glucosa, ≥99.5% (GC), BioXtra
Sigma-Aldrich
Colesterol, powder, BioReagent, suitable for cell culture, ≥99%
USP
D-(+)-Glucosa, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Colesterol, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
D-(+)-Glucosa, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Supelco
D-(+)-Glucosa, analytical standard
Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
Sigma-Aldrich
D-(+)-Glucosa, ACS reagent
SAFC
Colesterol, derivado vegetal, SyntheChol®
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
D-(+)-Glucosa, suitable for mouse embryo cell culture, ≥99.5% (GC)
Supelco
D-(+)-Glucosa, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Colesterol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-(+)-Glucosa, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
D-(+)-Glucosa, 99.9 atom % 16O, 99.9 atom % 12C
SAFC
Colesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
D-(+)-Glucosa, tested according to Ph. Eur.